Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191451
Status:
COMPLETED
Last Update Posted:
2009-11-20
First Post:
2005-09-12
Brief Title:
A Study of Gemcitabine and Carboplatin Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive HER2 Patients With Metastatic Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Organization Data
Organization:
Eli Lilly and Company
Class:
INDUSTRY
Study ID:
9397
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Eli Lilly and Company
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Chief Medical Officer
Old Organization:
Eli Lilly